LAS VEGAS ( Courtroom View Network) -- A jury awarded $182.6M in compensatory and punitive damages against pharmaceutical maker Teva ( TEVA)and two of Teva's distributors, Baxter ( BAX) and McKesson ( MCK).The case involved a 2008 Hepatitis C outbreak in Las Vegas among patients at a group of Endoscopy clinics owned by subsequently indicted physician Dipak Desai. The clinics improperly used containers of the anesthetic Propofol for multiple patients. This "double-dosing" allowed blood-borne pathogens -- Hepatitis C virus in particular -- to be transferred among patients. >>For case history and video archive, click here: Sacks v. Endoscopy Center For the plaintiffs, Robert Eglet (Mainor Eglet) argued that Teva should not have supplied "jumbo" 50 ml Propofol vials to endoscopy clinics that would only be performing brief procedures typically requiring 20ml or less of the anesthetic, because the larger vials created a substantial risk that the clinic would re-use vials rather than dispose of the mostly-full vials after each procedure. According to Mr. Eglet, Teva used the larger vials because it was more profitable to do so, even though the pharmaceutical companies knew of the risk that endoscopy clinics would double-dose if given the larger vials. Similar outbreaks had previously occurred at other endoscopy centers. Also for the plaintiffs, Will Kemp (Kemp Jones & Coulthard) told the jury, "In 1995, the most prestigious medical journal in the world says 'eliminate or modify the 50ml vial,'" and yet Teva failed to do so. A drug manufacturer has a continuous duty to monitor the medical literature and other sources of information, Mr. Kemp explained. However, Teva was unaware of many articles, including a report from the Centers for Disease Control, indicating that larger anesthesia vials created a health risk. Moreover, said Mr. Kemp, Teva's failure to monitor had a demonstrable impact, because after they learned of the risks, endoscopy center physicians stopped ordering the larger vials. On behalf of the manufacturer, Teva, Mark Tully (Goodwin Proctor) told the jury that there is nothing unique about a 50ml vial that causes it to be misused. Any size vial can be misused. However, said Mr. Tully, large vials can also be broken down into smaller syringes, which lets them be divided between multiple patients without risk. So the risk to patients is not created by the vial size or the desire to multi-dose, but the by "outrageous" and unanticipated misuse at the endoscopy center.